CAR-T Long Term Follow Up (LTFU) Study
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy
Novartis Pharmaceuticals
1,400 participants
Nov 2, 2015
INTERVENTIONAL
Conditions
Summary
Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all patients exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion to assess the risk of delayed adverse events (AEs), monitor for replication competent lentivirus (RCL) and assess long-term efficacy, including vector persistence.
Eligibility
Inclusion Criteria2
- All patients who have received a CAR-T therapy and completed or discontinued early from a Novartis sponsored treatment protocol that utilized CAR-T cells or from any CAR-T trial sponsored by the University of Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR technology.
- Patients who have provided informed consent for the long term follow up study prior to their study participation .
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Lentiviral-based CAR-T cell therapy
Locations(118)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02445222